89bio (NASDAQ:ETNB) Experiences Significant Surge in Trading Volume - What Lies Ahead?

89bio, Inc. (NASDAQ:ETNB) witnessed a notable spike in its trading volume on Friday, with approximately 1,705,503 shares changing hands. This remarkable figure is an 81% increase compared to the previous session's volume of 943,383 shares. The stock price reached $8.00 during trading, after closing at $7.89 the day before.

Analysts Reassess Price Targets

Several research firms have expressed their views on ETNB recently. Cantor Fitzgerald maintained an "overweight" rating while setting a price target of $29.00 for 89bio shares in a report released on September 20. Similarly, HC Wainwright reiterated a "buy" rating with the same price target on November 11. Raymond James, however, revised their price objective for 89bio from $53.00 down to $49.00 while giving it a "strong-buy" rating in a report dated November 8. Currently, two analysts have assigned a hold rating, four have a buy rating, and one has a strong buy rating. According to MarketBeat.com, the consensus rating for this stock is a "Moderate Buy" with an average price target set at $30.33.

89bio Stock Shows 1.3% Increase

At present, 89bio has a market capitalization of approximately $847.95 million. The stock carries a P/E ratio of -2.71 and has a beta value of 1.12. The company’s 50-day moving average price stands at $8.34, while the 200-day moving average price is $8.38. Financially, 89bio maintains a debt-to-equity ratio of 0.09, with both its current and quick ratios sitting at 11.66, which indicates a solid liquidity position.

Insider Purchasing Activity

In related news, CEO Rohan Palekar purchased 10,000 shares of 89bio stock on November 22 at an average price of $8.35 per share. This amounted to a total investment of $83,500. Following this transaction, the CEO now owns a total of 466,236 shares, valued at approximately $3,893,070.60, which represents a 2.19% increase in his holdings. This transaction has been duly reported in filings with the SEC. Currently, company insiders hold about 2.80% of the total stock.

Institutional Investors Adjust Their Holdings

A number of institutional investors have recently restructured their investments in 89bio. Quest Partners LLC boosted its stake by an impressive 226.2% during the second quarter, now holding 8,113 shares worth $65,000 after acquiring an additional 5,626 shares. Moreover, Northwestern Mutual Wealth Management Co. invested in 89bio for the first time in the second quarter, valuing their shares at roughly $66,000. China Universal Asset Management Co. Ltd. increased its holdings in 89bio by 76.2% during the third quarter, owning 20,370 shares worth $151,000 after purchasing another 8,810 shares. Other significant investments include Intech Investment Management LLC, which bought new shares valued at around $160,000, and SG Americas Securities LLC, which also took a new position valued at approximately $203,000 in the second quarter.

Company Overview

89bio, Inc. is a clinical-stage biopharmaceutical firm focused on developing and marketing therapies aimed at treating liver diseases and cardio-metabolic conditions. The company's leading product candidate is pegozafermin, a modified version of fibroblast growth factor 21, specifically designed for addressing nonalcoholic steatohepatitis as well as severe hypertriglyceridemia.

Investment Considerations

As investors assess their options, many are contemplating the potential for 89bio amidst its unique trading volume surge. With a current analyst consensus of a "Moderate Buy" rating, stakeholders must weigh these insights against their investment strategies.

stocks, trading, investment